A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the agency's website, as the Trump administration halts DEI initiatives.

Research that has not yet been peer-reviewed shows the newest blood test is more than 80% accurate in detecting colon cancer in people who had the disease. The test is 90% accurate in ruling out cancer in healthy adults, according to the study published Monday in the Journal of Clinical Oncology.

Just a few weeks ago on January 15, the Food and Drug Administration (FDA) under the Biden administration revoked authorization of the additive red dye 3, meaning it will be banned from foods and drugs.

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety of tumors.

In his first Senate confirmation hearing to be secretary of the Department of Health and Human Services, Robert F. Kennedy Jr. repeated claims we have written about before on vaccines and chronic disease.

As part of the second Trump Administration's diversity witchhunt, cancer research and other crucial projects have been paused indefinitely. As Mother Jones reports, this administration's pushback against diversity,

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday.

Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the US and European Union for some breast cancer patients whose cancer spread after receiving treatment, or whose disease returned after surgery.

Over 35 years after the first study linking the artificial food dye Red 3 to thyroid cancer in rats was published, the U.S. is beginning to phase it out of foods and drugs.

Zentalis Pharmaceuticals said it would cut 40% of its workforce as part of a restructuring to support the late-stage development of its cancer-drug azenosertib.

Studies going back decades have shown a potential link between artificial food dyes and attention deficit hyperactivity disorder symptoms in kids.

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: NCT04494425 ).